Relievant lands FDA green light for clinical trial of Intracept back pain therapy

June 3, 2013 by Sony Salzman

Relievant Medsystems expands to 20 U.S. sites its SMART clinical trial for back pain therapy with the Intracept basivertebral nerve ablation.


Relievant Medsystems won FDA investigational device exemption for its Intracept back pain therapy, paving the way for the medical device company to continue its SMART pivotal clinical trial.

The Redwood City, Calif.-based company said it will expand the 200-patient randomized, controlled trial to 20 sites across the U.S., where it will evaluate the Intracept therapy in treatment of chronic low back pain.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.